Medexus Pharmaceuticals Inc. - MEDXF STOCK NEWS

Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) has announced it will host a conference call at 8:00 am Eastern Time on Wednesday, June 26, 2024, to discuss its fourth fiscal quarter and fiscal year results ending March 31, 2024. The financial statements and MD&A will be filed after markets close on June 25, 2024. Interested parties can join the call via toll-free numbers for Canadian and U.S. callers or through an international number with the access code 160589. A live webcast will be available on Medexus's investor section of their website. A replay will be accessible approximately one hour post-call and until July 3, 2024, through specified phone numbers and on the website until June 26, 2025.

On June 6, 2024, Medexus Pharmaceuticals announced that the US FDA has accepted for review the resubmission of the New Drug Application (NDA) for treosulfan, a drug used in combination with fludarabine for stem cell transplantation in both adult and pediatric patients. The review is expected to be completed by October 30, 2024. This resubmission includes additional data from a pivotal Phase 3 clinical trial. CEO Ken d'Entremont expressed optimism about the drug's approval and its potential to significantly impact Medexus's revenue if approved in the US. Treosulfan has already been successfully commercialized in Canada under the brand name Trecondyv® since September 2021.

Medexus Pharmaceuticals and medac have concluded the litigation regarding the Canadian patent for Metoject® after a trial in January 2023. The Federal Court of Canada declined to uphold the patent, leading to no meaningful changes for Medexus's business. The company remains optimistic about the impact of this outcome on their product and operations.

Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) announces participation in the 2024 Bloom Burton & Co. Healthcare Investor Conference. Company executives to present on April 17, 2024, at 1:30 PM Eastern time in Toronto, Ontario.

Medexus Pharmaceuticals receives FDA approval for expanded indication of IXINITY for pediatric patients under 12 years of age with hemophilia B, based on Phase 3/4 data showing safety and efficacy.

Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) announced its operating and financial results for the third fiscal quarter ended December 31, 2023. The company reported a revenue of $25.2 million and $87.1 million for the three- and nine-month periods, with a decrease of $3.5 million and an increase of $7.6 million compared to the same periods in 2022. The adjusted EBITDA was $3.2 million and $15.1 million for the three- and nine-month periods, showing a decrease of $2.0 million and an increase of $3.8 million compared to the prior year. The available liquidity was $8.2 million as of December 31, 2023, and the operating income was $1.6 million and $10.0 million for the three- and nine-month periods, with a decrease of $1.3 million and an increase of $5.1 million compared to the previous year. The net loss was $0.5 million and $1.0 million for the three- and nine-month periods, indicating an improvement of $1.0 million and $4.6 million compared to the same periods in 2022. Adjusted net loss showed an improvement as well, with $0.5 million and $1.1 million for the three- and nine-month periods, compared to $0.9 million and $7.3 million for the same periods in 2022.

Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) will host a conference call on February 8, 2024, to discuss its third fiscal quarter results. Financial statements and MD&A will be filed on February 7, 2024. The call will be available via webcast and replay, with access details provided.

Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) announces Health Canada's acceptance for review of their new drug submission for terbinafine hydrochloride nail lacquer to treat fungal nail infections, aiming for a commercial launch in the first half of calendar year 2025. The Canadian topical fungicides market is estimated to be C$88 million annually, positioning the product for significant market potential.

Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) announced a 9.4% increase in fiscal Q2 2024 revenue over fiscal Q2 2023, reaching $30.3 million. Adjusted EBITDA rose by 26.2% to $5.3 million, while operating income increased by $1.7 million. However, the net loss improved by $1.6 million. Medexus also secured $37.5 million in liquidity, utilizing it to repay convertible debentures and complete a bought-deal public offering.